I work from memory, so folks can add the details, but Cytodyn had a strategy to do the hardest trial, questioning whether Leronlimab could show significance in a Mild/Moderate population, BECAUSE this was the hardest to prove. This would open some other doors based on Milds Moderates versus Placebo, if my memory serves. (80% of Covid patients are M/M (Dr JL), sub-Q, outpatient, stopping progression).

The confidence, no cockiness, to go this route and prove it is part of the plan.

“If these patients weren't ever hospitalized, if they weren't in the hospital to begin with, I guess we can't say that Leronlimab sent them out the door faster than the placebo patients. How disappointing!”